Shots:
The US FDA has granted Orphan Drug Designation (ODD) to asedebart (Lu AG13909) for the treatment of endogenous Cushing's syndrome
Lundbeck is evaluating efficacy and safety of asedebart in proof-of-concept trials for Cushing's disease & classic congenital adrenal hyperplasia (CAH)
Asedebart is a humanized anti-ACTH monoclonal antibody that blocks ACTH signaling at the adrenal…
